Although my hub is BLF - I spotted a thread on hear.
People on cancer treatments by and large bot not all will receive a letter.
THE LETTER HAS NIL TO DO WITH THE TEXT MOST OF US HAVE RECEIVED.
QUOTE: A copy of the letter sent to patients can be found in Annex 3. The patients of your
practice that have been contacted can be identified through an “at high risk” indicator
code that has been applied to each patient record by your clinical system supplier.
Your supplier will inform you of the code they have used, which should be treated as
temporary until a definitive list of COVID-19 ‘at risk’ SNOMED codes is released.
Your GP System supplier will also provide a report that will list those patients that
have been centrally identified as being at high risk. You should have this by 23
March. We ask that you review this report for accuracy and, where any of these
patients have dementia, a learning disability or autism, that you provide appropriate
additional support to them to ensure they continue receiving access to care.
We have taken a two-pronged approach to identification of people on
immunosuppression therapies sufficient to significantly increase the risk of infection
(category 5). All patients on the following medications have been centrally identified
and will be contacted via the letter:
• Mycophenolate (both types)
• Tacrolimus [UNQUOTE]
Hope this helps..